These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 25688782)

  • 21. Improved in-hospital outcomes in acute coronary syndromes (unstable angina/non-ST segment elevation myocardial infarction) despite similar TIMI risk scores.
    Almeda FQ; Hendel RC; Nathan S; Meyer PM; Calvin JE; Klein LW
    J Invasive Cardiol; 2003 Sep; 15(9):502-6. PubMed ID: 12947210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
    ; Yusuf S; Mehta SR; Chrolavicius S; Afzal R; Pogue J; Granger CB; Budaj A; Peters RJ; Bassand JP; Wallentin L; Joyner C; Fox KA
    N Engl J Med; 2006 Apr; 354(14):1464-76. PubMed ID: 16537663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in Gender Differences in Cardiac Care and Outcome After Acute Myocardial Infarction in Western Sweden: A Report From the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART).
    Redfors B; Angerås O; Råmunddal T; Petursson P; Haraldsson I; Dworeck C; Odenstedt J; Ioaness D; Ravn-Fischer A; Wellin P; Sjöland H; Tokgozoglu L; Tygesen H; Frick E; Roupe R; Albertsson P; Omerovic E
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
    Fox KA; Bassand JP; Mehta SR; Wallentin L; Theroux P; Piegas LS; Valentin V; Moccetti T; Chrolavicius S; Afzal R; Yusuf S;
    Ann Intern Med; 2007 Sep; 147(5):304-10. PubMed ID: 17785485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of bridging therapy with fondaparinux versus low-molecular-weight heparin in patients undergoing atrial fibrillation ablation.
    Zhang F; Zhao D; Peng X; Yang H; Zhu T; Huang F; Peng J
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Apr; 34(4):448-52. PubMed ID: 24752085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D; Mahaffey KW; Moliterno DJ; Harrington RA; Yadav JS; Pieper KS; Gallup D; Dyke C; Roe MT; Berdan L; Lauer MS; Mänttäri M; White HD; Califf RM; Topol EJ
    Am Heart J; 2002 Dec; 144(6):995-1002. PubMed ID: 12486423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction.
    Shen L; Shah BR; Nam A; Holmes D; Alexander KP; Bhatt DL; Ho PM; Peterson ED; He B; Roe MT
    Am Heart J; 2014 Jun; 167(6):840-5. PubMed ID: 24890533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A Meta-Analysis.
    Qiao J; Zhang X; Zhang J; Li P; Xu B; Wang S; Jiang H; Shen Y; Wang K
    Cardiology; 2016; 133(3):163-72. PubMed ID: 26605908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation.
    Yusuf S; Mehta SR; Xie C; Ahmed RJ; Xavier D; Pais P; Zhu J; Liu L;
    JAMA; 2005 Jan; 293(4):427-35. PubMed ID: 15671427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.
    Eikelboom JW; Anand SS; Malmberg K; Weitz JI; Ginsberg JS; Yusuf S
    Lancet; 2000 Jun; 355(9219):1936-42. PubMed ID: 10859038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management and mortality in patients with non-ST-segment elevation vs. ST-segment elevation myocardial infarction. Data from the Malopolska Registry of Acute Coronary Syndromes.
    Dziewierz A; Siudak Z; Dykla D; Rakowski T; Mielecki W; Dubiel JS; Dudek D
    Kardiol Pol; 2009 Feb; 67(2):115-20; discussion 121-2. PubMed ID: 19288373
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events.
    Collet JP; Montalescot G; Agnelli G; Van de Werf F; Gurfinkel EP; López-Sendón J; Laufenberg CV; Klutman M; Gowda N; Gulba D;
    Eur Heart J; 2005 Nov; 26(21):2285-93. PubMed ID: 15932908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Jin Z; Wang L; Ramasamy S; Poddar KL; Minami Y; Park JY; Choi CU; Oh DJ; Jeong MH;
    J Cardiol; 2012 Jan; 59(1):22-9. PubMed ID: 22079855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Admission international normalized ratio levels, early treatment strategies, and major bleeding risk among non-ST-segment-elevation myocardial infarction patients on home warfarin therapy: insights from the National Cardiovascular Data Registry.
    Subherwal S; Peterson ED; Chen AY; Roe MT; Washam JB; Gage BF; Bach RG; Bhatt DL; Wiviott SD; Lopes RD; Alexander KP; Wang TY
    Circulation; 2012 Mar; 125(11):1414-23. PubMed ID: 22319105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of presenting electrocardiographic findings on the treatment and outcomes of patients with non-ST-segment elevation myocardial infarction.
    Patel JH; Gupta R; Roe MT; Peng SA; Wiviott SD; Saucedo JF
    Am J Cardiol; 2014 Jan; 113(2):256-61. PubMed ID: 24290492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes.
    Alexander KP; Chen AY; Roe MT; Newby LK; Gibson CM; Allen-LaPointe NM; Pollack C; Gibler WB; Ohman EM; Peterson ED;
    JAMA; 2005 Dec; 294(24):3108-16. PubMed ID: 16380591
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years.
    Puymirat E; Schiele F; Steg PG; Blanchard D; Isorni MA; Silvain J; Goldstein P; Guéret P; Mulak G; Berard L; Bataille V; Cattan S; Ferrières J; Simon T; Danchin N;
    Int J Cardiol; 2014 Nov; 177(1):281-6. PubMed ID: 25499393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing between Enoxaparin and Fondaparinux for the management of patients with acute coronary syndrome: A systematic review and meta-analysis.
    Bundhun PK; Shaik M; Yuan J
    BMC Cardiovasc Disord; 2017 May; 17(1):116. PubMed ID: 28482804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor Xa inactivation in acute coronary syndrome.
    Barantke M; Bonnemeier H
    Curr Pharm Des; 2008; 14(12):1186-90. PubMed ID: 18473865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention.
    Brieger D; Collet JP; Silvain J; Landivier A; Barthélémy O; Beygui F; Bellemain-Appaix A; Mercadier A; Choussat R; Vignolles N; Costagliola D; Montalescot G
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):182-90. PubMed ID: 20578166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.